Prosecution Insights
Last updated: November 12, 2026
Application No. 18/885,403

ANTI-BIOFOULING COMPOSITION

Non-Final OA §102§103§112
Filed
Sep 13, 2024
Priority
Sep 15, 2023 — provisional 63/538,625
Examiner
GEMBEH, SHIRLEY V
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Montana Technological University
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
97%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
1040 granted / 1647 resolved
+3.1% vs TC avg
Strong +34% interview lift
Without
With
+33.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
50 currently pending
Career history
1694
Total Applications
across all art units

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I (claims 1-9) in the reply filed on 9/29/26 is acknowledged. Claims 10-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Group, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 9/29/26 with a condition to rejoin if the elected subject matter is allowed. Claim Rejections - 35 USC § 112. Claims1-2 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-2 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection Here, applicant has not described a reasonable number of members of the genus now claimed that might identify some agents that fall within the scope of the claim. The instant claims are often referred to as “reach-through” claims, where an applicant attempts to obtain patent protection on an invention not yet discovered. The Court of Appeals for the Federal Circuit addressed claims of this sort in great detail at the University of Rochester v. G.D. Searle and Co. (69 USPQ 2nd 1886, CAFC 2004). In Rochester, the Federal Circuit upheld the district court's ruling that patent claims which recited administration of compounds not disclosed, but rather to be identified in a screening assay, were invalid on their face. While the instant claims are drawn to compositions composition, comprising: a polymeric mixture comprising a hydrophobic component and a hydrophilic component, wherein the hydrophobic component has a lower water solubility than the hydrophilic component; and one or more molecules for disrupting bacterial communication, the situation is analogous to that in Rochester. Since the specification does not disclose to the public the structures claimed, it does not meet the written description requirement of 35 USC § 112, first paragraph. To avoid this rejection the Examiner, suggest that claim 3 be included as part of claim 1. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-5 and 9 is/are rejected under 35 U.S.C. 102(a2) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Bose et al. (Materials Today Chemistry 8(2018 110-120). Bose teaches a composition comprising PCL-PEG coated with curcumin (see abstract) as required by instant claims 1-4), wherein the curcumin is the main active component derived from the rhizomes of turmeric plant (CurcumalongaL.) i.e., a molecule for disrupting bacteria(as required) and therefore a molecule for disrupting bacterial communication (as required by instant claims1and 7) with a ratio of 1:1 (see para.2.1.2 drug polymer coating as required by instant claim 4). With regards to instant claim 5, the compounds PCL-PEG are anticipated or intrinsically to be of the claimed molecular weight of 5, 000 to 100,000; and wherein the hydrophilic component comprises polyethylene glycol having a molecular weight ranging from 200 to 1,000,000. Additionally, Bose teaches that the polymer solution and the curcumin underwent mixing (see para 2.3.2, as required by instant claim 9). However, Bose fails to teach, wherein the one or more molecules for disrupting bacterial communication comprises an anti-quorum sensing molecule, a derivative, or analogue thereof; or a quorum quenching molecule, a derivative, or analogue thereof Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-5 is/are rejected under 35 U.S.C. 103 as being unpatentable over Bose et al. (Materials Today Chemistry 8(2018 110-120) in view of Lowe et al. (Polym. Chem. (2015) 5(2) 198-212) and further in view of Bouyahya et al. Molecules (2022) 27(5)1484 Bose teaches a composition comprising PCL-PEG coated with curcumin (see abstract) as required by instant claims 1-4), wherein the curcumin is the main active component derived from the rhizomes of turmeric plant (CurcumalongaL.) i.e., a molecule for disrupting bacteria(as required) and therefore a molecule for disrupting bacterial communication (as required by instant claims1and 7) with a ratio of 1:1 (see para.2.1.2 drug polymer coating as required by instant claim 4). With regards to instant claim 5, the compounds PCL-PEG are anticipated or intrinsically to be of the claimed molecular weight of 5, 000 to 100,000; and wherein the hydrophilic component comprises polyethylene glycol having a molecular weight ranging from 200 to 1,000,000. Additionally, Bose teaches that the polymer solution and the curcumin underwent mixing (see para 2.3.2, as required by instant claim 9). However, Bose fails to teach, wherein the one or more molecules for disrupting bacterial communication comprises an anti-quorum sensing molecule, a derivative, or analogue thereof; or a quorum quenching molecule, a derivative, or analogue thereof Lowe teaches that microbial absorption on biomedical systems and PEG polymer is the most widely used antifouling agent (see abstract). Bouyaha teaches quorum (i.e., QS0 is an inter cellular communication system between the same strain or different strains that co-ordinates the transcriptional regulation of genes responsible for several vital functions of these microorganisms (see abstract and Introduction). Therefore, one of ordinary skills in the art One would have been motivated to combine these references and make the modification because they are drawn to same technical fields (constituted with same ingredients and share common utilities, and pertinent to the problem which applicant concerns about. MPEP 2141.01(a) Additionally, the person of ordinary skill in the art, having the laboratory walls hung would have been motivated to combine the teachings of the cited prior art and form a composition comprising by expanding the teachings of Bose above , incorporating Lowe’s and Bouyaha’ s teaching to result in the instant claimed invention with a reasonable expectation of success The person of ordinary skill in the art would have been motivated to do so to attain the known advantages of the advantages treatments as taught by the references, and further would have been motivated to monitor the results of the treatment using multiple parameters, to get a better overall indication of efficacy. Accordingly, the invention as claimed is prima facie obvious. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHIRLEY V GEMBEH whose telephone number is (571)272-8504. The examiner can normally be reached M-F 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A. Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SHIRLEY V GEMBEH/Primary Examiner, Art Unit 1615 10/22/26
Read full office action

Prosecution Timeline

Sep 13, 2024
Application Filed
Oct 26, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778127
RAINFASTNESS ADJUVANT FORMULATION CONTAINING A SULFOPOLYMER
4y 7m to grant Granted Nov 03, 2026
Patent 12778897
BIO-MICROBUR THERAPEUTIC DELIVERY PLATFORM
2y 11m to grant Granted Nov 03, 2026
Patent 12778866
BETTER-FEELING ALCOHOL-BASED RUB-IN HAND SANITIZER COMPOSITION
2y 10m to grant Granted Nov 03, 2026
Patent 12774303
COMPOSITIONS AND METHODS FOR IN SITU-FORMING GELS FOR WOUND HEALING AND TISSUE REGENERATION
4y 2m to grant Granted Oct 27, 2026
Patent 12773469
METHODS AND MATERIALS FOR EMBOLIZATION
3y 7m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
97%
With Interview (+33.8%)
Low
PTA Risk
Based on 1647 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month